Expression and function of the TL1A/DR3 axis in chronic lymphocytic leukemia
PDF | HTML | How to cite
Metrics: PDF 1303 views | HTML 2042 views | ?
Chiara Cavallini1, Ornella Lovato1, Anna Bertolaso2, Elisa Zoratti1,3, Giorgio Malpeli2,3, Elda Mimiola4, Martina Tinelli4, Fiorenza Aprili5, Cristina Tecchio4, Omar Perbellini4, Aldo Scarpa2,3, Alberto Zamò2, Marco Antonio Cassatella6, Giovanni Pizzolo4, Maria Teresa Scupoli1,3,4
1Interdepartmental Laboratory of Medical Research (LURM), University of Verona, Verona, Italy
2Department of Pathology and Diagnostics, Section of Pathological Anatomy, University of Verona, Verona, Italy
3Applied Research on Cancer-Network (ARC-NET), University of Verona, Verona, Italy
4Department of Medicine, Section of Hematology, University of Verona, Verona, Italy
5Department of Pathology and Diagnostics, Laboratory of Cytogenetics, Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy
6Department of Pathology and Diagnostics, Section of General Pathology, University of Verona, Verona, Italy
Maria Teresa Scupoli, e-mail: [email protected]
Keywords: leukemia, microenvironment, chronic lymphocytic leukemia, cytokines, cytokine receptors
Received: July 31, 2015 Accepted: September 04, 2015 Published: September 15, 2015
TNF-like ligand 1A (TL1A) and its unique receptor death receptor 3 (DR3) acts as broad T-cell costimulator involved in regulatory mechanisms of adaptive immune response under physiological and pathological settings. Moreover, we have recently shown that TL1A negatively regulates B-cell proliferation. Despite increasing interest on the TL1A/DR3-axis functions, very little is known on its expression and role in leukemia. In this study, we investigated the expression and function of TL1A/DR3 axis in chronic lymphocytic leukemia (CLL). DR3 was differentially expressed in activated CLL cells and predominantly detected in patients with early clinical stage disease. Soluble TL1A has been revealed in the sera of CLL patients where higher TL1A levels were associated with early stage disease. T cells, monocytes and leukemic B cells have been identified as major sources of TL1A in CLL. The relevance of these findings has been sustained by functional data showing that exogenous TL1A reduces CLL proliferation induced by stimulation of the B cell receptor. Overall, these data document the expression of the TL1A/DR3 axis in early-stage CLL. They also identify a novel function for TL1A as a negative regulator of leukemic cell proliferation that may influence the CLL physiopathology and clinical outcome at an early-stage disease.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.